| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dry Eye Syndromes | 144 | 2026 | 294 | 32.370 |
Why?
|
| Tears | 103 | 2026 | 186 | 17.760 |
Why?
|
| Conjunctiva | 90 | 2026 | 197 | 16.260 |
Why?
|
| Epithelium, Corneal | 86 | 2025 | 174 | 12.910 |
Why?
|
| Cornea | 96 | 2025 | 566 | 10.000 |
Why?
|
| Goblet Cells | 33 | 2024 | 104 | 8.700 |
Why?
|
| Sjogren's Syndrome | 36 | 2026 | 108 | 7.800 |
Why?
|
| Lacrimal Apparatus | 44 | 2025 | 126 | 6.290 |
Why?
|
| Keratoconjunctivitis Sicca | 26 | 2026 | 50 | 6.230 |
Why?
|
| Ophthalmic Solutions | 33 | 2026 | 89 | 4.080 |
Why?
|
| Cytokines | 47 | 2024 | 1354 | 3.880 |
Why?
|
| Conjunctival Diseases | 11 | 2026 | 30 | 3.650 |
Why?
|
| Eye | 19 | 2023 | 227 | 3.540 |
Why?
|
| Interferon-gamma | 20 | 2024 | 542 | 3.480 |
Why?
|
| Meibomian Glands | 19 | 2021 | 43 | 3.350 |
Why?
|
| Disease Models, Animal | 56 | 2026 | 4684 | 3.300 |
Why?
|
| Cyclosporine | 16 | 2026 | 130 | 3.220 |
Why?
|
| Corneal Diseases | 20 | 2023 | 94 | 3.060 |
Why?
|
| Mice, Inbred C57BL | 72 | 2025 | 4762 | 3.000 |
Why?
|
| Epithelial Cells | 38 | 2021 | 900 | 2.500 |
Why?
|
| Dendritic Cells | 14 | 2024 | 437 | 2.330 |
Why?
|
| Inflammation | 29 | 2023 | 1500 | 2.240 |
Why?
|
| Gene Expression Regulation | 26 | 2026 | 2357 | 2.150 |
Why?
|
| Desiccation | 19 | 2026 | 46 | 2.150 |
Why?
|
| Eyelid Diseases | 11 | 2015 | 58 | 1.970 |
Why?
|
| Immunity, Innate | 13 | 2024 | 411 | 1.960 |
Why?
|
| Mice | 106 | 2026 | 18504 | 1.960 |
Why?
|
| Mucins | 10 | 2024 | 69 | 1.930 |
Why?
|
| CD4-Positive T-Lymphocytes | 15 | 2020 | 496 | 1.930 |
Why?
|
| RNA, Messenger | 45 | 2024 | 2573 | 1.920 |
Why?
|
| Animals | 141 | 2026 | 34460 | 1.910 |
Why?
|
| Eye Proteins | 15 | 2025 | 239 | 1.890 |
Why?
|
| Keratoconjunctivitis | 8 | 2021 | 19 | 1.880 |
Why?
|
| Contact Lenses | 9 | 2021 | 40 | 1.870 |
Why?
|
| Matrix Metalloproteinase 9 | 19 | 2015 | 139 | 1.860 |
Why?
|
| Anti-Inflammatory Agents | 17 | 2025 | 304 | 1.860 |
Why?
|
| Interleukin-13 | 6 | 2024 | 96 | 1.850 |
Why?
|
| Blinking | 6 | 2023 | 27 | 1.830 |
Why?
|
| Keratitis | 16 | 2021 | 104 | 1.780 |
Why?
|
| Immunosuppressive Agents | 15 | 2014 | 666 | 1.770 |
Why?
|
| Humans | 300 | 2026 | 131967 | 1.760 |
Why?
|
| Visual Acuity | 38 | 2024 | 535 | 1.750 |
Why?
|
| Lacrimal Apparatus Diseases | 10 | 2017 | 41 | 1.750 |
Why?
|
| Autoimmune Diseases | 6 | 2024 | 275 | 1.700 |
Why?
|
| Interleukin-1 | 15 | 2025 | 131 | 1.650 |
Why?
|
| Cells, Cultured | 50 | 2026 | 2963 | 1.630 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 9 | 2014 | 84 | 1.620 |
Why?
|
| Corneal Ulcer | 11 | 2026 | 56 | 1.590 |
Why?
|
| Fluorescein | 21 | 2023 | 39 | 1.580 |
Why?
|
| Osmolar Concentration | 19 | 2021 | 148 | 1.550 |
Why?
|
| Limbus Corneae | 17 | 2021 | 32 | 1.530 |
Why?
|
| Doxycycline | 12 | 2016 | 115 | 1.520 |
Why?
|
| Fluorophotometry | 20 | 2026 | 31 | 1.500 |
Why?
|
| Female | 176 | 2026 | 71316 | 1.500 |
Why?
|
| Macrophages | 6 | 2026 | 663 | 1.460 |
Why?
|
| Blepharitis | 5 | 2023 | 9 | 1.460 |
Why?
|
| Middle Aged | 120 | 2026 | 28911 | 1.450 |
Why?
|
| Apoptosis | 12 | 2022 | 1860 | 1.440 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 26 | 2018 | 97 | 1.400 |
Why?
|
| Eye Diseases | 10 | 2019 | 108 | 1.400 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 33 | 2024 | 792 | 1.390 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 33 | 2017 | 1236 | 1.370 |
Why?
|
| Aged | 91 | 2026 | 21279 | 1.350 |
Why?
|
| Mucin 5AC | 5 | 2020 | 21 | 1.340 |
Why?
|
| Corneal Topography | 15 | 2018 | 140 | 1.340 |
Why?
|
| Immune Tolerance | 5 | 2020 | 158 | 1.280 |
Why?
|
| Adult | 111 | 2026 | 31734 | 1.270 |
Why?
|
| Lubricant Eye Drops | 4 | 2019 | 10 | 1.260 |
Why?
|
| Stress, Physiological | 14 | 2016 | 262 | 1.250 |
Why?
|
| Carnitine | 4 | 2015 | 72 | 1.230 |
Why?
|
| Epidermal Growth Factor | 13 | 2012 | 116 | 1.210 |
Why?
|
| Mice, Knockout | 37 | 2020 | 3864 | 1.200 |
Why?
|
| Cell Count | 18 | 2021 | 217 | 1.180 |
Why?
|
| Male | 136 | 2026 | 65357 | 1.170 |
Why?
|
| Erythritol | 3 | 2014 | 4 | 1.170 |
Why?
|
| Tomography, Optical Coherence | 7 | 2021 | 463 | 1.160 |
Why?
|
| Stem Cells | 18 | 2021 | 713 | 1.160 |
Why?
|
| Microscopy, Confocal | 20 | 2024 | 363 | 1.150 |
Why?
|
| Th1 Cells | 7 | 2019 | 156 | 1.140 |
Why?
|
| MAP Kinase Signaling System | 6 | 2008 | 305 | 1.120 |
Why?
|
| Azithromycin | 3 | 2015 | 47 | 1.090 |
Why?
|
| Aged, 80 and over | 45 | 2026 | 6922 | 1.080 |
Why?
|
| Conjunctivitis, Allergic | 9 | 2020 | 17 | 1.060 |
Why?
|
| Antigen-Presenting Cells | 4 | 2019 | 133 | 1.060 |
Why?
|
| TRPV Cation Channels | 2 | 2026 | 47 | 1.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 16 | 2022 | 643 | 1.020 |
Why?
|
| Signal Transduction | 27 | 2022 | 4693 | 1.010 |
Why?
|
| Real-Time Polymerase Chain Reaction | 19 | 2024 | 533 | 0.990 |
Why?
|
| Monocytes | 3 | 2026 | 337 | 0.970 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2024 | 180 | 0.960 |
Why?
|
| T-Lymphocytes | 12 | 2023 | 1790 | 0.960 |
Why?
|
| Botulinum Toxins, Type A | 2 | 2022 | 165 | 0.950 |
Why?
|
| Prostheses and Implants | 3 | 2012 | 148 | 0.940 |
Why?
|
| RNA | 10 | 2017 | 530 | 0.940 |
Why?
|
| Blotting, Western | 21 | 2016 | 1018 | 0.920 |
Why?
|
| Aging | 13 | 2020 | 1269 | 0.920 |
Why?
|
| Transforming Growth Factor beta | 10 | 2013 | 462 | 0.890 |
Why?
|
| Nerve Growth Factor | 2 | 2019 | 22 | 0.880 |
Why?
|
| Betaine | 2 | 2014 | 19 | 0.870 |
Why?
|
| Eye Infections, Fungal | 7 | 2018 | 68 | 0.870 |
Why?
|
| Protein Precursors | 12 | 2017 | 147 | 0.870 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 6 | 2008 | 85 | 0.860 |
Why?
|
| Keratomileusis, Laser In Situ | 6 | 2010 | 84 | 0.840 |
Why?
|
| Th2 Cells | 8 | 2019 | 186 | 0.840 |
Why?
|
| Transcriptome | 4 | 2021 | 1141 | 0.840 |
Why?
|
| Orbital Neoplasms | 1 | 2024 | 49 | 0.830 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2024 | 61 | 0.830 |
Why?
|
| Osmotic Pressure | 6 | 2024 | 24 | 0.830 |
Why?
|
| Epithelium | 20 | 2011 | 343 | 0.820 |
Why?
|
| Cell Differentiation | 16 | 2021 | 1951 | 0.810 |
Why?
|
| Administration, Topical | 16 | 2025 | 132 | 0.800 |
Why?
|
| Trigeminal Nerve Diseases | 2 | 2021 | 5 | 0.800 |
Why?
|
| Burns, Chemical | 6 | 2023 | 30 | 0.790 |
Why?
|
| Lacerations | 1 | 2023 | 32 | 0.770 |
Why?
|
| Dexamethasone | 6 | 2016 | 262 | 0.770 |
Why?
|
| Saline Solution, Hypertonic | 3 | 2008 | 21 | 0.770 |
Why?
|
| Keratoconus | 5 | 2011 | 48 | 0.760 |
Why?
|
| Eye Infections, Bacterial | 14 | 2017 | 79 | 0.760 |
Why?
|
| Conjunctivitis | 3 | 2015 | 21 | 0.760 |
Why?
|
| Calcineurin Inhibitors | 2 | 2020 | 23 | 0.750 |
Why?
|
| Blepharospasm | 1 | 2022 | 47 | 0.740 |
Why?
|
| Glucocorticoids | 7 | 2016 | 350 | 0.730 |
Why?
|
| Endophthalmitis | 17 | 2000 | 49 | 0.730 |
Why?
|
| Interleukin-17 | 8 | 2016 | 128 | 0.730 |
Why?
|
| Tretinoin | 2 | 2021 | 97 | 0.720 |
Why?
|
| Surveys and Questionnaires | 13 | 2026 | 4058 | 0.720 |
Why?
|
| Interleukin-12 | 3 | 2018 | 124 | 0.720 |
Why?
|
| Wound Healing | 10 | 2019 | 477 | 0.700 |
Why?
|
| Electric Stimulation Therapy | 2 | 2025 | 85 | 0.700 |
Why?
|
| Matrix Metalloproteinases | 5 | 2017 | 62 | 0.700 |
Why?
|
| Receptors, Nicotinic | 1 | 2022 | 132 | 0.690 |
Why?
|
| Case-Control Studies | 15 | 2021 | 3453 | 0.690 |
Why?
|
| Dermatitis, Atopic | 3 | 2020 | 55 | 0.690 |
Why?
|
| Autoantigens | 3 | 2012 | 104 | 0.690 |
Why?
|
| Membrane Proteins | 12 | 2017 | 1612 | 0.680 |
Why?
|
| Prospective Studies | 24 | 2022 | 6522 | 0.680 |
Why?
|
| Retinoids | 1 | 2021 | 29 | 0.680 |
Why?
|
| Bone Marrow Cells | 4 | 2018 | 244 | 0.680 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 4 | 2010 | 23 | 0.680 |
Why?
|
| Transforming Growth Factor beta2 | 3 | 2010 | 12 | 0.670 |
Why?
|
| Anti-Bacterial Agents | 21 | 2017 | 2578 | 0.650 |
Why?
|
| Rosacea | 6 | 2001 | 13 | 0.650 |
Why?
|
| Toll-Like Receptors | 6 | 2014 | 82 | 0.650 |
Why?
|
| Prosthesis Implantation | 2 | 2012 | 148 | 0.640 |
Why?
|
| Vision Disorders | 6 | 2020 | 197 | 0.640 |
Why?
|
| Astigmatism | 7 | 2011 | 113 | 0.630 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 7 | 2018 | 53 | 0.630 |
Why?
|
| Transforming Growth Factor beta1 | 8 | 2015 | 139 | 0.630 |
Why?
|
| Adoptive Transfer | 12 | 2020 | 236 | 0.620 |
Why?
|
| Interferon Type I | 2 | 2020 | 115 | 0.620 |
Why?
|
| B7-2 Antigen | 2 | 2019 | 16 | 0.620 |
Why?
|
| Th17 Cells | 7 | 2019 | 95 | 0.610 |
Why?
|
| Herpes Zoster Ophthalmicus | 4 | 2024 | 11 | 0.610 |
Why?
|
| Inflammation Mediators | 7 | 2020 | 228 | 0.600 |
Why?
|
| Candidiasis | 4 | 2018 | 132 | 0.570 |
Why?
|
| Interleukin-1beta | 6 | 2023 | 159 | 0.560 |
Why?
|
| Candida parapsilosis | 1 | 2018 | 3 | 0.560 |
Why?
|
| Methylprednisolone | 4 | 2006 | 97 | 0.550 |
Why?
|
| Gene Expression | 9 | 2016 | 1503 | 0.550 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 4 | 2016 | 17 | 0.550 |
Why?
|
| Glycoproteins | 1 | 2020 | 349 | 0.550 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 2 | 2016 | 29 | 0.540 |
Why?
|
| Biomarkers | 24 | 2020 | 3415 | 0.530 |
Why?
|
| Anterior Eye Segment | 2 | 2017 | 24 | 0.530 |
Why?
|
| Microbiota | 4 | 2019 | 444 | 0.530 |
Why?
|
| Disease Management | 4 | 2020 | 565 | 0.530 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2016 | 122 | 0.520 |
Why?
|
| Severity of Illness Index | 10 | 2018 | 3095 | 0.520 |
Why?
|
| Corneal Opacity | 2 | 2024 | 21 | 0.520 |
Why?
|
| Cell Survival | 8 | 2024 | 854 | 0.520 |
Why?
|
| Cell Degranulation | 1 | 2017 | 28 | 0.510 |
Why?
|
| Eye Burns | 5 | 2017 | 16 | 0.510 |
Why?
|
| Autoimmunity | 5 | 2017 | 182 | 0.510 |
Why?
|
| Herpesvirus 4, Human | 11 | 1994 | 646 | 0.510 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 5 | 2010 | 75 | 0.500 |
Why?
|
| Homeostasis | 4 | 2021 | 714 | 0.500 |
Why?
|
| Receptor, ErbB-3 | 3 | 2001 | 18 | 0.500 |
Why?
|
| Unfolded Protein Response | 1 | 2016 | 63 | 0.480 |
Why?
|
| Mouth Mucosa | 1 | 2016 | 48 | 0.480 |
Why?
|
| Cell Proliferation | 12 | 2024 | 2483 | 0.470 |
Why?
|
| Immunohistochemistry | 15 | 2019 | 1610 | 0.470 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 3 | 2011 | 15 | 0.470 |
Why?
|
| Young Adult | 22 | 2026 | 10108 | 0.470 |
Why?
|
| Dacryocystitis | 5 | 2018 | 22 | 0.470 |
Why?
|
| Environment, Controlled | 1 | 2015 | 7 | 0.460 |
Why?
|
| ATP-Binding Cassette Transporters | 6 | 2008 | 191 | 0.450 |
Why?
|
| Cornified Envelope Proline-Rich Proteins | 7 | 2011 | 19 | 0.450 |
Why?
|
| Immunoenzyme Techniques | 12 | 2010 | 237 | 0.450 |
Why?
|
| Permeability | 7 | 2018 | 120 | 0.450 |
Why?
|
| Transglutaminases | 4 | 2008 | 27 | 0.450 |
Why?
|
| Treatment Outcome | 21 | 2026 | 13011 | 0.440 |
Why?
|
| Ophthalmic Nerve | 3 | 2018 | 6 | 0.440 |
Why?
|
| Cholinergic Antagonists | 3 | 2013 | 47 | 0.440 |
Why?
|
| Eye Infections, Viral | 6 | 2024 | 25 | 0.430 |
Why?
|
| Flow Cytometry | 10 | 2015 | 772 | 0.430 |
Why?
|
| Protective Agents | 1 | 2014 | 36 | 0.430 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2016 | 234 | 0.420 |
Why?
|
| Chemokines | 4 | 2010 | 127 | 0.420 |
Why?
|
| ErbB Receptors | 5 | 2026 | 298 | 0.410 |
Why?
|
| Emulsions | 5 | 2026 | 70 | 0.410 |
Why?
|
| Receptors, CXCR3 | 2 | 2013 | 23 | 0.410 |
Why?
|
| Imidazoles | 5 | 2015 | 222 | 0.410 |
Why?
|
| Mice, Inbred BALB C | 11 | 2020 | 1020 | 0.410 |
Why?
|
| Cell Membrane Permeability | 4 | 2012 | 67 | 0.410 |
Why?
|
| Inflammasomes | 3 | 2023 | 157 | 0.400 |
Why?
|
| NF-kappa B | 10 | 2023 | 450 | 0.390 |
Why?
|
| Cranial Nerve Diseases | 2 | 2018 | 28 | 0.390 |
Why?
|
| Double-Blind Method | 6 | 2026 | 1638 | 0.390 |
Why?
|
| Lymphocyte Activation | 8 | 2019 | 681 | 0.380 |
Why?
|
| Herpesviridae Infections | 6 | 1994 | 140 | 0.380 |
Why?
|
| Chemokine CXCL11 | 3 | 2018 | 9 | 0.380 |
Why?
|
| Chemokine CXCL9 | 3 | 2018 | 14 | 0.380 |
Why?
|
| Tissue Kallikreins | 1 | 2012 | 7 | 0.370 |
Why?
|
| Cataract | 1 | 2013 | 152 | 0.370 |
Why?
|
| Postoperative Complications | 10 | 2014 | 3135 | 0.370 |
Why?
|
| Sclera | 6 | 2021 | 45 | 0.370 |
Why?
|
| Scleritis | 5 | 2004 | 10 | 0.360 |
Why?
|
| Chemokine CXCL10 | 3 | 2016 | 52 | 0.360 |
Why?
|
| Eyelids | 4 | 2012 | 108 | 0.360 |
Why?
|
| Killer Cells, Natural | 2 | 2012 | 344 | 0.360 |
Why?
|
| In Situ Nick-End Labeling | 5 | 2011 | 122 | 0.350 |
Why?
|
| Matrix Metalloproteinase 3 | 7 | 2014 | 18 | 0.350 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2007 | 189 | 0.350 |
Why?
|
| Receptors, Chemokine | 2 | 2011 | 47 | 0.350 |
Why?
|
| Keratoplasty, Penetrating | 10 | 2024 | 48 | 0.350 |
Why?
|
| Sensation | 5 | 2009 | 49 | 0.350 |
Why?
|
| Neuromuscular Agents | 1 | 2012 | 69 | 0.340 |
Why?
|
| Plasma | 2 | 2022 | 103 | 0.340 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2026 | 1626 | 0.340 |
Why?
|
| Intestinal Mucosa | 1 | 2016 | 765 | 0.340 |
Why?
|
| Cell Size | 2 | 2008 | 79 | 0.340 |
Why?
|
| T-Lymphocyte Subsets | 3 | 2019 | 199 | 0.340 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 4 | 2020 | 23 | 0.340 |
Why?
|
| Corneal Wavefront Aberration | 1 | 2011 | 13 | 0.340 |
Why?
|
| Artificial Organs | 1 | 2010 | 11 | 0.340 |
Why?
|
| Interleukin-33 | 4 | 2020 | 21 | 0.330 |
Why?
|
| Lipopolysaccharides | 6 | 2019 | 302 | 0.330 |
Why?
|
| Dehydration | 2 | 2007 | 41 | 0.330 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor Receptors | 3 | 2010 | 5 | 0.330 |
Why?
|
| Paresthesia | 1 | 2010 | 9 | 0.330 |
Why?
|
| Zymosan | 1 | 2010 | 3 | 0.330 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 3 | 2023 | 129 | 0.330 |
Why?
|
| Autoantibodies | 3 | 2012 | 466 | 0.330 |
Why?
|
| Staining and Labeling | 6 | 2013 | 172 | 0.330 |
Why?
|
| Caspases | 5 | 2011 | 157 | 0.320 |
Why?
|
| Anti-Allergic Agents | 2 | 2014 | 29 | 0.320 |
Why?
|
| Vitrectomy | 7 | 2006 | 41 | 0.320 |
Why?
|
| Androstadienes | 2 | 2014 | 50 | 0.320 |
Why?
|
| Fluorescent Antibody Technique | 10 | 2018 | 420 | 0.320 |
Why?
|
| Eye Injuries | 4 | 2006 | 49 | 0.320 |
Why?
|
| Protein Kinase C-alpha | 1 | 2010 | 19 | 0.320 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2022 | 293 | 0.320 |
Why?
|
| Interleukins | 5 | 2021 | 121 | 0.320 |
Why?
|
| Recombinant Proteins | 7 | 2019 | 1319 | 0.320 |
Why?
|
| Retrospective Studies | 28 | 2021 | 17703 | 0.320 |
Why?
|
| Toll-Like Receptor 4 | 3 | 2016 | 140 | 0.310 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2018 | 866 | 0.310 |
Why?
|
| Butyrates | 2 | 2022 | 41 | 0.310 |
Why?
|
| Myopia | 3 | 2006 | 120 | 0.310 |
Why?
|
| Corneal Transplantation | 7 | 2013 | 43 | 0.310 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 1141 | 0.300 |
Why?
|
| GTP-Binding Proteins | 2 | 2008 | 161 | 0.300 |
Why?
|
| Polyendocrinopathies, Autoimmune | 1 | 2009 | 9 | 0.300 |
Why?
|
| Nerve Regeneration | 1 | 2009 | 76 | 0.300 |
Why?
|
| Interleukin-18 | 2 | 2023 | 78 | 0.300 |
Why?
|
| Antigens, Plant | 3 | 2019 | 45 | 0.290 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 3 | 2020 | 198 | 0.290 |
Why?
|
| Drug Therapy, Combination | 9 | 2014 | 1173 | 0.290 |
Why?
|
| Disability Evaluation | 1 | 2010 | 197 | 0.290 |
Why?
|
| Contact Lens Solutions | 1 | 2008 | 5 | 0.290 |
Why?
|
| Lissamine Green Dyes | 4 | 2013 | 8 | 0.290 |
Why?
|
| Receptors, Interleukin-1 Type I | 1 | 2008 | 2 | 0.290 |
Why?
|
| Biomedical Engineering | 1 | 2008 | 21 | 0.290 |
Why?
|
| Transcription Factors | 6 | 2015 | 2442 | 0.290 |
Why?
|
| Primary Cell Culture | 4 | 2018 | 107 | 0.290 |
Why?
|
| Oxidative Stress | 5 | 2017 | 810 | 0.290 |
Why?
|
| Cautery | 2 | 2023 | 6 | 0.280 |
Why?
|
| Sodium | 2 | 2010 | 281 | 0.280 |
Why?
|
| Isotonic Solutions | 1 | 2008 | 37 | 0.280 |
Why?
|
| Ophthalmology | 4 | 2018 | 179 | 0.280 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2016 | 240 | 0.280 |
Why?
|
| Nasolacrimal Duct | 3 | 2017 | 24 | 0.280 |
Why?
|
| Disease Susceptibility | 2 | 2020 | 283 | 0.280 |
Why?
|
| Phenylalanine | 3 | 2018 | 126 | 0.280 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p57 | 2 | 2012 | 13 | 0.280 |
Why?
|
| Cell Communication | 2 | 2020 | 191 | 0.270 |
Why?
|
| Immunity, Mucosal | 3 | 2014 | 90 | 0.270 |
Why?
|
| Immunoglobulin G | 4 | 2012 | 812 | 0.270 |
Why?
|
| Follow-Up Studies | 14 | 2019 | 5298 | 0.270 |
Why?
|
| Antifungal Agents | 5 | 2018 | 298 | 0.270 |
Why?
|
| Phenotype | 12 | 2019 | 4531 | 0.270 |
Why?
|
| Amino Acids, Diamino | 2 | 2024 | 2 | 0.270 |
Why?
|
| Nerve Growth Factors | 2 | 2007 | 69 | 0.270 |
Why?
|
| Receptor, trkA | 1 | 2007 | 18 | 0.270 |
Why?
|
| Cytochromes c | 1 | 2007 | 51 | 0.260 |
Why?
|
| Proto-Oncogene Proteins c-ets | 2 | 2018 | 57 | 0.260 |
Why?
|
| Vitreous Body | 8 | 1995 | 56 | 0.260 |
Why?
|
| Intermediate Filament Proteins | 2 | 2006 | 23 | 0.260 |
Why?
|
| Sialoglycoproteins | 3 | 2001 | 43 | 0.260 |
Why?
|
| Autophagy | 2 | 2020 | 424 | 0.260 |
Why?
|
| Dibenzoxepins | 1 | 2006 | 1 | 0.260 |
Why?
|
| Dibenzazepines | 1 | 2006 | 3 | 0.260 |
Why?
|
| Histamine H1 Antagonists, Non-Sedating | 1 | 2006 | 3 | 0.260 |
Why?
|
| Stress, Mechanical | 2 | 2007 | 179 | 0.260 |
Why?
|
| Histamine H1 Antagonists | 1 | 2006 | 13 | 0.260 |
Why?
|
| Lactoferrin | 5 | 2001 | 76 | 0.250 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2006 | 13 | 0.250 |
Why?
|
| Administration, Intranasal | 2 | 2017 | 130 | 0.250 |
Why?
|
| Dysbiosis | 2 | 2019 | 149 | 0.250 |
Why?
|
| Plant Extracts | 2 | 2019 | 139 | 0.250 |
Why?
|
| Peptide Fragments | 3 | 2011 | 782 | 0.250 |
Why?
|
| Cyclohexenes | 1 | 2026 | 12 | 0.250 |
Why?
|
| Xerophthalmia | 3 | 2014 | 8 | 0.240 |
Why?
|
| Polymerase Chain Reaction | 8 | 2015 | 1489 | 0.240 |
Why?
|
| Serum | 1 | 2006 | 45 | 0.240 |
Why?
|
| Forkhead Transcription Factors | 5 | 2020 | 372 | 0.240 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2026 | 17 | 0.240 |
Why?
|
| Diabetic Retinopathy | 2 | 2006 | 84 | 0.240 |
Why?
|
| Cell Movement | 6 | 2016 | 886 | 0.240 |
Why?
|
| Enzyme Activation | 4 | 2014 | 590 | 0.240 |
Why?
|
| Chemokine CCL5 | 2 | 2021 | 53 | 0.240 |
Why?
|
| Stevens-Johnson Syndrome | 2 | 2016 | 18 | 0.240 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2005 | 138 | 0.240 |
Why?
|
| Immunophenotyping | 4 | 2018 | 337 | 0.240 |
Why?
|
| Interleukin-8 | 3 | 2020 | 207 | 0.240 |
Why?
|
| Reactive Oxygen Species | 4 | 2017 | 520 | 0.230 |
Why?
|
| Prevalence | 4 | 2023 | 2697 | 0.230 |
Why?
|
| TRPM Cation Channels | 1 | 2025 | 11 | 0.230 |
Why?
|
| Organ Size | 2 | 2021 | 437 | 0.230 |
Why?
|
| Occludin | 4 | 2011 | 19 | 0.230 |
Why?
|
| Aqueous Humor | 4 | 1999 | 17 | 0.230 |
Why?
|
| Homeodomain Proteins | 4 | 2018 | 569 | 0.230 |
Why?
|
| Corneal Neovascularization | 2 | 2023 | 13 | 0.230 |
Why?
|
| Antibodies, Monoclonal | 8 | 2020 | 1012 | 0.230 |
Why?
|
| Collagen Type IV | 1 | 2005 | 20 | 0.230 |
Why?
|
| Caspase 3 | 4 | 2007 | 127 | 0.230 |
Why?
|
| Fluorescent Dyes | 5 | 2012 | 252 | 0.230 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 1 | 2004 | 1 | 0.220 |
Why?
|
| Ulcer | 2 | 2004 | 51 | 0.220 |
Why?
|
| Cross-Over Studies | 2 | 2017 | 333 | 0.220 |
Why?
|
| Mucous Membrane | 4 | 2013 | 88 | 0.220 |
Why?
|
| Collagenases | 3 | 2004 | 16 | 0.220 |
Why?
|
| Sensory Receptor Cells | 1 | 2025 | 61 | 0.220 |
Why?
|
| Phagocytes | 1 | 2024 | 25 | 0.220 |
Why?
|
| Immunotherapy | 1 | 2010 | 767 | 0.220 |
Why?
|
| Candida albicans | 3 | 2015 | 88 | 0.220 |
Why?
|
| Reproducibility of Results | 9 | 2023 | 2992 | 0.210 |
Why?
|
| Terminology as Topic | 2 | 2025 | 227 | 0.210 |
Why?
|
| Administration, Ophthalmic | 2 | 2025 | 8 | 0.210 |
Why?
|
| Specimen Handling | 2 | 1997 | 149 | 0.210 |
Why?
|
| Gastrointestinal Microbiome | 3 | 2022 | 838 | 0.210 |
Why?
|
| Hyperesthesia | 1 | 2004 | 2 | 0.210 |
Why?
|
| Multiple Myeloma | 1 | 2007 | 217 | 0.210 |
Why?
|
| Adaptive Immunity | 2 | 2017 | 98 | 0.210 |
Why?
|
| Air | 1 | 2004 | 23 | 0.210 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2004 | 72 | 0.210 |
Why?
|
| Delphi Technique | 4 | 2025 | 264 | 0.200 |
Why?
|
| Antirheumatic Agents | 1 | 2005 | 118 | 0.200 |
Why?
|
| Sensitivity and Specificity | 7 | 2011 | 2148 | 0.200 |
Why?
|
| Mice, Inbred NOD | 3 | 2016 | 301 | 0.200 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 2004 | 51 | 0.200 |
Why?
|
| Mite Infestations | 1 | 2023 | 2 | 0.200 |
Why?
|
| Mites | 1 | 2023 | 7 | 0.200 |
Why?
|
| Contact Lenses, Extended-Wear | 3 | 2000 | 5 | 0.200 |
Why?
|
| Eye Infections, Parasitic | 1 | 2023 | 8 | 0.200 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2005 | 289 | 0.200 |
Why?
|
| Biopsy | 3 | 2024 | 1252 | 0.200 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 4 | 2008 | 125 | 0.200 |
Why?
|
| Hormones | 1 | 2004 | 165 | 0.200 |
Why?
|
| HLA-DR Antigens | 5 | 2015 | 70 | 0.200 |
Why?
|
| Enzyme Inhibitors | 4 | 2007 | 566 | 0.190 |
Why?
|
| Cell Division | 5 | 2010 | 731 | 0.190 |
Why?
|
| Metalloendopeptidases | 1 | 2003 | 104 | 0.190 |
Why?
|
| Interferometry | 1 | 2022 | 21 | 0.190 |
Why?
|
| Cell Line | 6 | 2010 | 2607 | 0.190 |
Why?
|
| Sulfones | 3 | 2018 | 73 | 0.190 |
Why?
|
| Carrier Proteins | 3 | 2015 | 1025 | 0.190 |
Why?
|
| Organic Chemicals | 4 | 2015 | 58 | 0.190 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2026 | 620 | 0.190 |
Why?
|
| Lasers | 1 | 2023 | 114 | 0.190 |
Why?
|
| Nociceptors | 1 | 2022 | 14 | 0.190 |
Why?
|
| RNA, Small Interfering | 4 | 2012 | 664 | 0.190 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2015 | 152 | 0.190 |
Why?
|
| Genes, Regulator | 1 | 2022 | 45 | 0.180 |
Why?
|
| Lymphocytes | 3 | 2022 | 359 | 0.180 |
Why?
|
| Drug Delivery Systems | 4 | 2016 | 215 | 0.180 |
Why?
|
| Mycoses | 2 | 1997 | 113 | 0.180 |
Why?
|
| Histamine | 1 | 2022 | 52 | 0.180 |
Why?
|
| Prednisolone | 2 | 2001 | 69 | 0.180 |
Why?
|
| Biomedical Research | 2 | 2018 | 558 | 0.180 |
Why?
|
| Models, Biological | 4 | 2020 | 1396 | 0.180 |
Why?
|
| Fourier Analysis | 2 | 2012 | 55 | 0.180 |
Why?
|
| Cell Adhesion Molecules | 2 | 2015 | 227 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 3 | 2015 | 1307 | 0.180 |
Why?
|
| Corneal Dystrophies, Hereditary | 1 | 2021 | 8 | 0.180 |
Why?
|
| Paclitaxel | 1 | 2022 | 134 | 0.180 |
Why?
|
| Hyaluronic Acid | 2 | 2017 | 108 | 0.180 |
Why?
|
| Hypesthesia | 1 | 2001 | 11 | 0.180 |
Why?
|
| DNA Primers | 6 | 2013 | 609 | 0.180 |
Why?
|
| Sequence Analysis, RNA | 1 | 2024 | 421 | 0.180 |
Why?
|
| Mice, Transgenic | 3 | 2018 | 2368 | 0.180 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2021 | 60 | 0.170 |
Why?
|
| Matrix Metalloproteinase 8 | 2 | 2016 | 15 | 0.170 |
Why?
|
| Interleukin-12 Subunit p35 | 1 | 2021 | 6 | 0.170 |
Why?
|
| Germ-Free Life | 2 | 2018 | 61 | 0.170 |
Why?
|
| Vitamin A Deficiency | 1 | 2021 | 11 | 0.170 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2024 | 611 | 0.170 |
Why?
|
| Matrix Metalloproteinase 1 | 3 | 2009 | 23 | 0.170 |
Why?
|
| Sickness Impact Profile | 2 | 2013 | 40 | 0.170 |
Why?
|
| Autophagy-Related Protein-1 Homolog | 1 | 2020 | 10 | 0.170 |
Why?
|
| ROC Curve | 1 | 2023 | 622 | 0.170 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 366 | 0.170 |
Why?
|
| Transfection | 3 | 2008 | 960 | 0.170 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2021 | 76 | 0.170 |
Why?
|
| Bromodeoxyuridine | 4 | 2010 | 56 | 0.170 |
Why?
|
| Pterygium | 1 | 2000 | 3 | 0.170 |
Why?
|
| Vitamin A | 1 | 2021 | 57 | 0.170 |
Why?
|
| Consensus | 4 | 2025 | 530 | 0.170 |
Why?
|
| Contrast Sensitivity | 1 | 2000 | 33 | 0.160 |
Why?
|
| Metaplasia | 3 | 2009 | 216 | 0.160 |
Why?
|
| Trehalose | 1 | 2020 | 21 | 0.160 |
Why?
|
| Infectious Mononucleosis | 2 | 1993 | 13 | 0.160 |
Why?
|
| Cytoprotection | 4 | 2020 | 37 | 0.160 |
Why?
|
| Receptors, Interleukin-9 | 1 | 2020 | 2 | 0.160 |
Why?
|
| Adolescent | 20 | 2024 | 21008 | 0.160 |
Why?
|
| Interleukin-9 | 1 | 2020 | 7 | 0.160 |
Why?
|
| Humidity | 3 | 2015 | 25 | 0.160 |
Why?
|
| Uveitis | 1 | 2020 | 33 | 0.160 |
Why?
|
| Matrix Metalloproteinase 13 | 2 | 2014 | 9 | 0.160 |
Why?
|
| Reflex | 2 | 2017 | 36 | 0.160 |
Why?
|
| Antibodies | 3 | 2017 | 358 | 0.160 |
Why?
|
| Curcumin | 1 | 2020 | 43 | 0.160 |
Why?
|
| Pilot Projects | 3 | 2010 | 1457 | 0.160 |
Why?
|
| Myeloid Cells | 1 | 2021 | 114 | 0.160 |
Why?
|
| Carbachol | 2 | 1996 | 14 | 0.160 |
Why?
|
| Pyridines | 3 | 2007 | 260 | 0.160 |
Why?
|
| Contrast Media | 2 | 2000 | 492 | 0.160 |
Why?
|
| Refraction, Ocular | 2 | 2018 | 184 | 0.160 |
Why?
|
| Trigeminal Nerve | 2 | 1997 | 5 | 0.160 |
Why?
|
| Alkalies | 5 | 2017 | 24 | 0.150 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2013 | 339 | 0.150 |
Why?
|
| Neoplasm Proteins | 5 | 2007 | 677 | 0.150 |
Why?
|
| Flagellin | 3 | 2014 | 20 | 0.150 |
Why?
|
| Methylprednisolone Hemisuccinate | 1 | 1999 | 5 | 0.150 |
Why?
|
| Macrophage Activation | 1 | 2019 | 64 | 0.150 |
Why?
|
| Preservatives, Pharmaceutical | 1 | 1999 | 11 | 0.150 |
Why?
|
| Matrix Metalloproteinase 2 | 2 | 2014 | 88 | 0.150 |
Why?
|
| Ophthalmologic Surgical Procedures | 3 | 2018 | 96 | 0.150 |
Why?
|
| Keratitis, Dendritic | 4 | 1992 | 18 | 0.150 |
Why?
|
| Interleukin-27 | 1 | 2019 | 3 | 0.150 |
Why?
|
| Lens Capsule, Crystalline | 2 | 2017 | 24 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 2 | 2009 | 21 | 0.150 |
Why?
|
| OX40 Ligand | 3 | 2019 | 9 | 0.150 |
Why?
|
| Chromans | 1 | 2018 | 9 | 0.150 |
Why?
|
| Microscopy, Fluorescence | 2 | 2015 | 312 | 0.150 |
Why?
|
| Fluoresceins | 4 | 2002 | 31 | 0.150 |
Why?
|
| Polysaccharides, Bacterial | 4 | 2014 | 65 | 0.140 |
Why?
|
| Delayed-Action Preparations | 2 | 2016 | 121 | 0.140 |
Why?
|
| Benzoates | 1 | 2018 | 26 | 0.140 |
Why?
|
| Recurrence | 6 | 2012 | 1487 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 341 | 0.140 |
Why?
|
| Cell Culture Techniques | 4 | 2017 | 275 | 0.140 |
Why?
|
| Growth Substances | 1 | 1998 | 102 | 0.140 |
Why?
|
| DNA, Mitochondrial | 2 | 2017 | 241 | 0.140 |
Why?
|
| Antibodies, Viral | 6 | 1995 | 1174 | 0.140 |
Why?
|
| Immune System | 2 | 2009 | 99 | 0.140 |
Why?
|
| Receptors, Cytokine | 3 | 2019 | 64 | 0.140 |
Why?
|
| Caspase 1 | 3 | 2017 | 51 | 0.140 |
Why?
|
| Immunoblotting | 2 | 2016 | 291 | 0.140 |
Why?
|
| Injections, Subcutaneous | 2 | 2011 | 134 | 0.140 |
Why?
|
| DNA, Viral | 5 | 1997 | 452 | 0.140 |
Why?
|
| Prognosis | 10 | 2017 | 4961 | 0.140 |
Why?
|
| Biological Dressings | 2 | 2001 | 5 | 0.140 |
Why?
|
| Sex | 1 | 1997 | 7 | 0.130 |
Why?
|
| Interleukin-6 | 3 | 2020 | 419 | 0.130 |
Why?
|
| Blotting, Northern | 4 | 2005 | 236 | 0.130 |
Why?
|
| Symbiosis | 1 | 2018 | 95 | 0.130 |
Why?
|
| Simplexvirus | 6 | 1995 | 100 | 0.130 |
Why?
|
| Cell Separation | 3 | 2011 | 222 | 0.130 |
Why?
|
| beta-Defensins | 2 | 2014 | 12 | 0.130 |
Why?
|
| Ovalbumin | 1 | 2017 | 119 | 0.130 |
Why?
|
| Laser Therapy | 2 | 2018 | 239 | 0.130 |
Why?
|
| Ciliary Body | 1 | 2017 | 18 | 0.130 |
Why?
|
| Caspase 8 | 1 | 2017 | 26 | 0.130 |
Why?
|
| Nanoparticles | 1 | 2020 | 293 | 0.130 |
Why?
|
| Ultrasonics | 1 | 2017 | 31 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 388 | 0.130 |
Why?
|
| Itraconazole | 1 | 1997 | 24 | 0.130 |
Why?
|
| Hospitals, County | 1 | 2017 | 22 | 0.130 |
Why?
|
| Graft vs Host Disease | 1 | 2022 | 680 | 0.130 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2017 | 25 | 0.130 |
Why?
|
| Time Factors | 8 | 2020 | 6285 | 0.130 |
Why?
|
| Laser Coagulation | 1 | 2018 | 109 | 0.130 |
Why?
|
| Antimicrobial Cationic Peptides | 2 | 2014 | 38 | 0.130 |
Why?
|
| Muscarinic Agonists | 1 | 1996 | 5 | 0.130 |
Why?
|
| Cell Adhesion | 4 | 2016 | 312 | 0.130 |
Why?
|
| Corneal Injuries | 1 | 2017 | 35 | 0.130 |
Why?
|
| Hospitals, High-Volume | 1 | 2017 | 42 | 0.130 |
Why?
|
| Cysteamine | 1 | 2016 | 15 | 0.130 |
Why?
|
| Cystinosis | 1 | 2016 | 15 | 0.130 |
Why?
|
| Transduction, Genetic | 2 | 2008 | 279 | 0.120 |
Why?
|
| Analysis of Variance | 4 | 2014 | 955 | 0.120 |
Why?
|
| Hypersensitivity | 1 | 2019 | 231 | 0.120 |
Why?
|
| Mice, Nude | 3 | 2012 | 714 | 0.120 |
Why?
|
| Dogs | 3 | 2025 | 632 | 0.120 |
Why?
|
| Antioxidants | 2 | 2016 | 336 | 0.120 |
Why?
|
| Microscopy | 1 | 2017 | 122 | 0.120 |
Why?
|
| Up-Regulation | 5 | 2021 | 832 | 0.120 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2014 | 460 | 0.120 |
Why?
|
| Blueberry Plants | 1 | 2016 | 6 | 0.120 |
Why?
|
| Tongue | 1 | 2016 | 30 | 0.120 |
Why?
|
| Phosphoproteins | 3 | 2008 | 430 | 0.120 |
Why?
|
| Tissue Scaffolds | 1 | 2017 | 92 | 0.120 |
Why?
|
| Conjunctival Neoplasms | 1 | 1996 | 13 | 0.120 |
Why?
|
| Reference Values | 4 | 1998 | 692 | 0.120 |
Why?
|
| Connexin 43 | 4 | 2017 | 34 | 0.120 |
Why?
|
| Swine | 3 | 2025 | 1191 | 0.120 |
Why?
|
| Clusterin | 1 | 2015 | 11 | 0.120 |
Why?
|
| Integrin alpha Chains | 1 | 2015 | 15 | 0.120 |
Why?
|
| Ultraviolet Rays | 2 | 2006 | 195 | 0.120 |
Why?
|
| Flavonoids | 2 | 2007 | 83 | 0.120 |
Why?
|
| Carboxymethylcellulose Sodium | 1 | 2015 | 13 | 0.120 |
Why?
|
| Nasal Cavity | 1 | 1996 | 55 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 580 | 0.120 |
Why?
|
| Carcinoma in Situ | 1 | 1996 | 72 | 0.120 |
Why?
|
| Species Specificity | 2 | 2025 | 519 | 0.110 |
Why?
|
| Neutralization Tests | 2 | 2011 | 226 | 0.110 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2017 | 186 | 0.110 |
Why?
|
| Rabbits | 4 | 2025 | 633 | 0.110 |
Why?
|
| Corneal Stroma | 2 | 2012 | 75 | 0.110 |
Why?
|
| Societies, Medical | 2 | 2018 | 798 | 0.110 |
Why?
|
| CD4 Antigens | 2 | 2020 | 49 | 0.110 |
Why?
|
| Tissue and Organ Procurement | 1 | 2018 | 253 | 0.110 |
Why?
|
| Retinal Necrosis Syndrome, Acute | 1 | 1995 | 2 | 0.110 |
Why?
|
| Toxoplasmosis, Ocular | 1 | 1995 | 3 | 0.110 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 1993 | 95 | 0.110 |
Why?
|
| Environmental Exposure | 2 | 2017 | 291 | 0.110 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2014 | 15 | 0.110 |
Why?
|
| Nanotechnology | 1 | 2015 | 50 | 0.110 |
Why?
|
| Hot Temperature | 1 | 2015 | 144 | 0.110 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2014 | 25 | 0.110 |
Why?
|
| Observer Variation | 2 | 2010 | 319 | 0.110 |
Why?
|
| Single-Blind Method | 1 | 2015 | 241 | 0.110 |
Why?
|
| Adenovirus Infections, Human | 1 | 1995 | 60 | 0.110 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2012 | 43 | 0.110 |
Why?
|
| Biological Assay | 2 | 2010 | 108 | 0.110 |
Why?
|
| Photography | 2 | 1992 | 81 | 0.110 |
Why?
|
| Cosmetic Techniques | 1 | 2014 | 11 | 0.110 |
Why?
|
| Mitomycin | 1 | 2014 | 48 | 0.110 |
Why?
|
| Sodium Chloride | 1 | 2014 | 91 | 0.110 |
Why?
|
| Autopsy | 1 | 2014 | 119 | 0.110 |
Why?
|
| Receptors, CCR6 | 1 | 2013 | 6 | 0.100 |
Why?
|
| Hepatocyte Nuclear Factor 3-beta | 1 | 2013 | 26 | 0.100 |
Why?
|
| Histamine Antagonists | 1 | 2013 | 17 | 0.100 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2017 | 398 | 0.100 |
Why?
|
| gamma-Linolenic Acid | 1 | 2013 | 3 | 0.100 |
Why?
|
| Genetic Vectors | 2 | 2008 | 907 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 1264 | 0.100 |
Why?
|
| Microbial Sensitivity Tests | 7 | 2017 | 853 | 0.100 |
Why?
|
| Models, Animal | 3 | 2017 | 460 | 0.100 |
Why?
|
| Antigens, CD | 3 | 2012 | 418 | 0.100 |
Why?
|
| Piperidines | 1 | 2015 | 231 | 0.100 |
Why?
|
| Thrombospondin 1 | 1 | 2013 | 22 | 0.100 |
Why?
|
| Eye Protective Devices | 1 | 2013 | 11 | 0.100 |
Why?
|
| Phosphorylation | 2 | 2008 | 1572 | 0.100 |
Why?
|
| Coculture Techniques | 2 | 2012 | 240 | 0.100 |
Why?
|
| Keratins | 3 | 2010 | 51 | 0.100 |
Why?
|
| Trans-Activators | 3 | 2005 | 692 | 0.100 |
Why?
|
| Tumor Virus Infections | 1 | 1994 | 131 | 0.100 |
Why?
|
| Early Diagnosis | 1 | 2013 | 192 | 0.100 |
Why?
|
| Molecular Sequence Data | 7 | 2006 | 3616 | 0.100 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2017 | 589 | 0.100 |
Why?
|
| Tetracycline | 2 | 2008 | 75 | 0.100 |
Why?
|
| beta Catenin | 2 | 2012 | 209 | 0.100 |
Why?
|
| Refractive Surgical Procedures | 1 | 2013 | 40 | 0.100 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2013 | 81 | 0.100 |
Why?
|
| Culture Media, Conditioned | 3 | 2017 | 83 | 0.100 |
Why?
|
| Transcription, Genetic | 1 | 1998 | 1398 | 0.100 |
Why?
|
| Immunomodulation | 1 | 2013 | 80 | 0.090 |
Why?
|
| Neutrophils | 2 | 2016 | 369 | 0.090 |
Why?
|
| Refractive Errors | 1 | 2013 | 59 | 0.090 |
Why?
|
| Feeder Cells | 1 | 2012 | 9 | 0.090 |
Why?
|
| Staphylococcus aureus | 2 | 1993 | 485 | 0.090 |
Why?
|
| Prodrugs | 1 | 2012 | 56 | 0.090 |
Why?
|
| Feces | 1 | 2016 | 725 | 0.090 |
Why?
|
| Injections, Intraocular | 1 | 2012 | 7 | 0.090 |
Why?
|
| Complement C3b | 1 | 2012 | 7 | 0.090 |
Why?
|
| Kallikreins | 1 | 2012 | 26 | 0.090 |
Why?
|
| DNA-Binding Proteins | 5 | 2005 | 1964 | 0.090 |
Why?
|
| Antigens, Differentiation | 2 | 2011 | 68 | 0.090 |
Why?
|
| Base Sequence | 6 | 2006 | 2783 | 0.090 |
Why?
|
| Complement Activation | 1 | 2012 | 47 | 0.090 |
Why?
|
| Corneal Edema | 1 | 1992 | 11 | 0.090 |
Why?
|
| Surgical Instruments | 2 | 1992 | 56 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2015 | 489 | 0.090 |
Why?
|
| Keratin-12 | 2 | 2017 | 3 | 0.090 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2012 | 82 | 0.090 |
Why?
|
| Immunization, Passive | 1 | 2012 | 124 | 0.090 |
Why?
|
| Down-Regulation | 3 | 2012 | 659 | 0.090 |
Why?
|
| Receptors, Interferon | 1 | 2011 | 20 | 0.090 |
Why?
|
| Staphylococcal Infections | 3 | 1993 | 569 | 0.090 |
Why?
|
| Immunity, Humoral | 1 | 2012 | 76 | 0.090 |
Why?
|
| Chronic Disease | 3 | 2022 | 1239 | 0.090 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2011 | 21 | 0.090 |
Why?
|
| fas Receptor | 1 | 2011 | 43 | 0.090 |
Why?
|
| Diagnosis, Differential | 3 | 2007 | 1916 | 0.090 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2011 | 79 | 0.090 |
Why?
|
| Oculomotor Muscles | 1 | 2012 | 81 | 0.090 |
Why?
|
| Co-Repressor Proteins | 1 | 2011 | 38 | 0.090 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2011 | 105 | 0.090 |
Why?
|
| Prosthesis Fitting | 1 | 2011 | 11 | 0.090 |
Why?
|
| Genes, Dominant | 1 | 2011 | 253 | 0.090 |
Why?
|
| Prolapse | 1 | 2010 | 10 | 0.080 |
Why?
|
| Wounds, Penetrating | 2 | 1988 | 138 | 0.080 |
Why?
|
| Chemexfoliation | 1 | 1990 | 2 | 0.080 |
Why?
|
| Receptors, Cholinergic | 1 | 2011 | 77 | 0.080 |
Why?
|
| STAT6 Transcription Factor | 1 | 2010 | 32 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2013 | 397 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2013 | 432 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2011 | 2308 | 0.080 |
Why?
|
| Tissue Engineering | 1 | 2012 | 168 | 0.080 |
Why?
|
| Coloring Agents | 1 | 2011 | 72 | 0.080 |
Why?
|
| Nocardia Infections | 1 | 1990 | 13 | 0.080 |
Why?
|
| Biological Transport | 3 | 2012 | 333 | 0.080 |
Why?
|
| False Positive Reactions | 1 | 2011 | 143 | 0.080 |
Why?
|
| Loteprednol Etabonate | 2 | 2014 | 5 | 0.080 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 2 | 2001 | 55 | 0.080 |
Why?
|
| Mucin-4 | 2 | 2000 | 12 | 0.080 |
Why?
|
| Antibodies, Neutralizing | 2 | 2013 | 521 | 0.080 |
Why?
|
| Molecular Chaperones | 1 | 2011 | 173 | 0.080 |
Why?
|
| Lectins | 1 | 1990 | 50 | 0.080 |
Why?
|
| Adult Stem Cells | 1 | 2011 | 55 | 0.080 |
Why?
|
| Dextrans | 1 | 2010 | 45 | 0.080 |
Why?
|
| Vancomycin | 3 | 1992 | 225 | 0.080 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2010 | 55 | 0.080 |
Why?
|
| Antigen Presentation | 1 | 2010 | 118 | 0.080 |
Why?
|
| Photogrammetry | 1 | 1989 | 4 | 0.080 |
Why?
|
| Regeneration | 1 | 2012 | 231 | 0.080 |
Why?
|
| Referral and Consultation | 1 | 2013 | 564 | 0.080 |
Why?
|
| Streptococcal Infections | 1 | 1992 | 248 | 0.080 |
Why?
|
| Nerve Fibers | 1 | 2009 | 69 | 0.080 |
Why?
|
| Disease Progression | 3 | 2017 | 2226 | 0.080 |
Why?
|
| Gene Expression Profiling | 3 | 2012 | 1841 | 0.080 |
Why?
|
| Capsid Proteins | 1 | 1990 | 150 | 0.070 |
Why?
|
| Acanthamoeba Keratitis | 2 | 2008 | 16 | 0.070 |
Why?
|
| Immunoassay | 1 | 2009 | 133 | 0.070 |
Why?
|
| Chemokine CCL3 | 1 | 2008 | 17 | 0.070 |
Why?
|
| Sirolimus | 2 | 2020 | 231 | 0.070 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2008 | 17 | 0.070 |
Why?
|
| Defensins | 1 | 2008 | 7 | 0.070 |
Why?
|
| Adenoviridae | 2 | 2008 | 586 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2008 | 39 | 0.070 |
Why?
|
| Risk Factors | 5 | 2017 | 10998 | 0.070 |
Why?
|
| Hypertonic Solutions | 1 | 2008 | 21 | 0.070 |
Why?
|
| Economics, Pharmaceutical | 1 | 2008 | 5 | 0.070 |
Why?
|
| In Vitro Techniques | 3 | 2007 | 824 | 0.070 |
Why?
|
| Age Factors | 1 | 2015 | 2869 | 0.070 |
Why?
|
| Integrin beta1 | 2 | 2005 | 54 | 0.070 |
Why?
|
| Blood | 1 | 1988 | 100 | 0.070 |
Why?
|
| AIDS-Related Complex | 1 | 1987 | 2 | 0.070 |
Why?
|
| Fibroblasts | 1 | 2012 | 858 | 0.070 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 2007 | 15 | 0.070 |
Why?
|
| Receptor, Nerve Growth Factor | 1 | 2007 | 8 | 0.070 |
Why?
|
| Antigens, Viral | 5 | 1993 | 395 | 0.070 |
Why?
|
| Surface Properties | 2 | 1998 | 83 | 0.070 |
Why?
|
| Fibrosis | 1 | 2009 | 421 | 0.070 |
Why?
|
| Antibody Formation | 1 | 2008 | 270 | 0.070 |
Why?
|
| CD4-CD8 Ratio | 1 | 2007 | 11 | 0.070 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2010 | 405 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2025 | 1255 | 0.070 |
Why?
|
| Fecal Microbiota Transplantation | 2 | 2018 | 108 | 0.070 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2005 | 202 | 0.070 |
Why?
|
| Cataract Extraction | 5 | 1997 | 129 | 0.070 |
Why?
|
| Safety | 2 | 2005 | 216 | 0.060 |
Why?
|
| Cell Cycle | 2 | 2021 | 598 | 0.060 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2007 | 67 | 0.060 |
Why?
|
| Drug Combinations | 2 | 2000 | 280 | 0.060 |
Why?
|
| Olopatadine Hydrochloride | 1 | 2006 | 1 | 0.060 |
Why?
|
| Functional Laterality | 1 | 2008 | 184 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 795 | 0.060 |
Why?
|
| Drug Labeling | 1 | 1987 | 29 | 0.060 |
Why?
|
| Incidence | 4 | 2017 | 3352 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 3843 | 0.060 |
Why?
|
| Vitreoretinopathy, Proliferative | 1 | 2006 | 4 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2006 | 33 | 0.060 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2006 | 21 | 0.060 |
Why?
|
| Rose Bengal | 2 | 1997 | 16 | 0.060 |
Why?
|
| Cadaverine | 1 | 2006 | 4 | 0.060 |
Why?
|
| Depression, Chemical | 1 | 2006 | 35 | 0.060 |
Why?
|
| Genetic Therapy | 2 | 2008 | 726 | 0.060 |
Why?
|
| Immunoglobulins | 3 | 2019 | 159 | 0.060 |
Why?
|
| Anti-Infective Agents | 1 | 1989 | 265 | 0.060 |
Why?
|
| Stress, Psychological | 1 | 2011 | 564 | 0.060 |
Why?
|
| Necrosis | 4 | 2016 | 195 | 0.060 |
Why?
|
| HIV Infections | 2 | 1996 | 2042 | 0.060 |
Why?
|
| Cell Nucleus | 2 | 2012 | 567 | 0.060 |
Why?
|
| Stromal Cells | 3 | 2014 | 314 | 0.060 |
Why?
|
| Bacterial Infections | 4 | 1991 | 326 | 0.060 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2005 | 34 | 0.060 |
Why?
|
| Culture Media | 2 | 1996 | 175 | 0.060 |
Why?
|
| Nanostructures | 2 | 2016 | 64 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 88 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 1219 | 0.060 |
Why?
|
| Cytomegalovirus | 5 | 1995 | 259 | 0.060 |
Why?
|
| Rats | 2 | 2022 | 3462 | 0.060 |
Why?
|
| Infliximab | 1 | 2005 | 66 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 106 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 1228 | 0.060 |
Why?
|
| Cats | 1 | 2025 | 122 | 0.060 |
Why?
|
| Protein Array Analysis | 1 | 2005 | 107 | 0.060 |
Why?
|
| Tight Junctions | 1 | 2025 | 39 | 0.060 |
Why?
|
| Pseudomonas Infections | 3 | 1991 | 117 | 0.060 |
Why?
|
| DNA | 1 | 2010 | 1440 | 0.060 |
Why?
|
| Eye Injuries, Penetrating | 3 | 2000 | 16 | 0.060 |
Why?
|
| Suspensions | 1 | 2004 | 8 | 0.060 |
Why?
|
| Chemokine CCL20 | 2 | 2016 | 17 | 0.050 |
Why?
|
| Tonometry, Ocular | 1 | 2004 | 29 | 0.050 |
Why?
|
| Metalloproteases | 1 | 2004 | 14 | 0.050 |
Why?
|
| Comorbidity | 1 | 2010 | 1607 | 0.050 |
Why?
|
| Lymph Nodes | 3 | 2013 | 377 | 0.050 |
Why?
|
| Mice, Inbred Strains | 1 | 2004 | 297 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2013 | 3708 | 0.050 |
Why?
|
| Mechanoreceptors | 1 | 2004 | 12 | 0.050 |
Why?
|
| Myeloid Differentiation Factor 88 | 2 | 2016 | 98 | 0.050 |
Why?
|
| Surgical Flaps | 1 | 2006 | 187 | 0.050 |
Why?
|
| Etanercept | 1 | 2004 | 44 | 0.050 |
Why?
|
| Neurturin | 1 | 2003 | 3 | 0.050 |
Why?
|
| Child | 9 | 2017 | 26332 | 0.050 |
Why?
|
| Cathelicidins | 2 | 2014 | 13 | 0.050 |
Why?
|
| Retina | 1 | 1987 | 463 | 0.050 |
Why?
|
| Matrix Metalloproteinase 10 | 1 | 2003 | 1 | 0.050 |
Why?
|
| Matrix Metalloproteinase 11 | 1 | 2003 | 1 | 0.050 |
Why?
|
| Anesthetics, Local | 2 | 1997 | 89 | 0.050 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2003 | 83 | 0.050 |
Why?
|
| Child, Preschool | 6 | 2017 | 15066 | 0.050 |
Why?
|
| Discriminant Analysis | 1 | 2002 | 22 | 0.050 |
Why?
|
| Global Health | 1 | 2008 | 633 | 0.050 |
Why?
|
| Prosthesis Design | 2 | 2018 | 612 | 0.050 |
Why?
|
| Health Status Indicators | 1 | 2003 | 124 | 0.050 |
Why?
|
| Antiviral Agents | 2 | 2024 | 813 | 0.050 |
Why?
|
| Amphotericin B | 3 | 2000 | 90 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2003 | 64 | 0.050 |
Why?
|
| DNA Damage | 2 | 2017 | 527 | 0.050 |
Why?
|
| Cathepsins | 1 | 2022 | 26 | 0.050 |
Why?
|
| Health Surveys | 1 | 2003 | 263 | 0.050 |
Why?
|
| Coumarins | 1 | 2022 | 23 | 0.050 |
Why?
|
| Lung | 1 | 2010 | 1571 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2004 | 441 | 0.050 |
Why?
|
| Mice, Inbred CBA | 1 | 2002 | 27 | 0.050 |
Why?
|
| Lenses, Intraocular | 5 | 1993 | 215 | 0.050 |
Why?
|
| Collagen | 2 | 1995 | 289 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2023 | 234 | 0.050 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2022 | 36 | 0.050 |
Why?
|
| Fatty Acids, Volatile | 1 | 2022 | 45 | 0.040 |
Why?
|
| Quinazolines | 2 | 2013 | 181 | 0.040 |
Why?
|
| Muscarinic Antagonists | 1 | 2002 | 35 | 0.040 |
Why?
|
| Transcription Factor 4 | 2 | 2012 | 12 | 0.040 |
Why?
|
| Eye Banks | 2 | 2018 | 11 | 0.040 |
Why?
|
| Androgens | 1 | 2004 | 272 | 0.040 |
Why?
|
| Fluorometholone | 1 | 2001 | 2 | 0.040 |
Why?
|
| Colony-Forming Units Assay | 3 | 2006 | 63 | 0.040 |
Why?
|
| Denervation | 1 | 2001 | 26 | 0.040 |
Why?
|
| Hydrogen Peroxide | 1 | 2002 | 117 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 694 | 0.040 |
Why?
|
| Touch | 1 | 2001 | 40 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2001 | 710 | 0.040 |
Why?
|
| Amnion | 1 | 2001 | 41 | 0.040 |
Why?
|
| Lacrimal Duct Obstruction | 1 | 2001 | 20 | 0.040 |
Why?
|
| Autophagosomes | 1 | 2020 | 28 | 0.040 |
Why?
|
| Poly I-C | 2 | 2011 | 23 | 0.040 |
Why?
|
| Endothelium, Corneal | 2 | 1992 | 27 | 0.040 |
Why?
|
| Aminoglycosides | 2 | 1992 | 47 | 0.040 |
Why?
|
| Proteins | 2 | 1996 | 1028 | 0.040 |
Why?
|
| Acremonium | 1 | 2000 | 1 | 0.040 |
Why?
|
| Serratia marcescens | 1 | 2000 | 11 | 0.040 |
Why?
|
| Leukocyte Common Antigens | 1 | 2020 | 84 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2022 | 671 | 0.040 |
Why?
|
| Tight Junction Proteins | 1 | 2020 | 14 | 0.040 |
Why?
|
| Bacterial Capsules | 3 | 2005 | 42 | 0.040 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2000 | 39 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2020 | 111 | 0.040 |
Why?
|
| Protein Transport | 2 | 2012 | 362 | 0.040 |
Why?
|
| United States | 2 | 2014 | 11827 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2000 | 189 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2000 | 201 | 0.040 |
Why?
|
| Drug Carriers | 1 | 2020 | 117 | 0.040 |
Why?
|
| Gene Amplification | 2 | 1990 | 228 | 0.040 |
Why?
|
| Acute Disease | 3 | 2018 | 1153 | 0.040 |
Why?
|
| Surgical Wound Infection | 2 | 1993 | 271 | 0.040 |
Why?
|
| Aphakia, Postcataract | 2 | 1991 | 17 | 0.040 |
Why?
|
| Color | 1 | 1999 | 33 | 0.040 |
Why?
|
| Lysosomal-Associated Membrane Protein 3 | 1 | 2018 | 2 | 0.040 |
Why?
|
| Chemokine CXCL1 | 1 | 2018 | 15 | 0.040 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 1 | 2018 | 15 | 0.040 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 1998 | 17 | 0.040 |
Why?
|
| Beclin-1 | 1 | 2018 | 32 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2020 | 347 | 0.040 |
Why?
|
| B-Lymphocytes | 2 | 2012 | 527 | 0.040 |
Why?
|
| Infant | 4 | 2017 | 13332 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2026 | 1001 | 0.040 |
Why?
|
| Tissue Distribution | 2 | 2010 | 366 | 0.040 |
Why?
|
| Autonomic Nervous System | 1 | 1998 | 48 | 0.040 |
Why?
|
| Ligands | 2 | 2010 | 486 | 0.040 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 1998 | 46 | 0.030 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2018 | 97 | 0.030 |
Why?
|
| S Phase | 1 | 1998 | 73 | 0.030 |
Why?
|
| Retinal Detachment | 2 | 1988 | 42 | 0.030 |
Why?
|
| Aerosols | 1 | 1997 | 60 | 0.030 |
Why?
|
| Lidocaine | 1 | 1997 | 41 | 0.030 |
Why?
|
| Herpesvirus 3, Human | 2 | 1995 | 30 | 0.030 |
Why?
|
| Light | 1 | 2018 | 174 | 0.030 |
Why?
|
| Mitosporic Fungi | 1 | 1997 | 8 | 0.030 |
Why?
|
| Deubiquitinating Enzymes | 1 | 2017 | 11 | 0.030 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2017 | 43 | 0.030 |
Why?
|
| Oligonucleotide Probes | 2 | 1994 | 87 | 0.030 |
Why?
|
| Bacteria | 5 | 2003 | 541 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 3 | 1992 | 196 | 0.030 |
Why?
|
| Nasal Mucosa | 1 | 1997 | 83 | 0.030 |
Why?
|
| Cellular Senescence | 1 | 2019 | 217 | 0.030 |
Why?
|
| Cystine | 1 | 2016 | 16 | 0.030 |
Why?
|
| Mink | 1 | 1996 | 3 | 0.030 |
Why?
|
| Cholinergic Agents | 1 | 1996 | 10 | 0.030 |
Why?
|
| Random Allocation | 1 | 1997 | 423 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 1996 | 144 | 0.030 |
Why?
|
| Disease Transmission, Infectious | 1 | 1997 | 77 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2017 | 165 | 0.030 |
Why?
|
| Propionibacterium acnes | 2 | 1993 | 13 | 0.030 |
Why?
|
| Neutrophil Infiltration | 1 | 2016 | 65 | 0.030 |
Why?
|
| Integrin alpha4 | 1 | 2015 | 12 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2026 | 1545 | 0.030 |
Why?
|
| Epidermis | 1 | 2016 | 64 | 0.030 |
Why?
|
| Capnocytophaga | 2 | 1993 | 5 | 0.030 |
Why?
|
| Stilbenes | 1 | 2016 | 36 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 1998 | 338 | 0.030 |
Why?
|
| Culture Techniques | 1 | 1995 | 75 | 0.030 |
Why?
|
| Integrin alpha4beta1 | 1 | 2015 | 26 | 0.030 |
Why?
|
| Acetylcysteine | 1 | 1996 | 79 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1996 | 228 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 1995 | 84 | 0.030 |
Why?
|
| Oxygenases | 1 | 2015 | 4 | 0.030 |
Why?
|
| Triamcinolone | 1 | 1995 | 13 | 0.030 |
Why?
|
| Galectin 3 | 1 | 2015 | 31 | 0.030 |
Why?
|
| Proteoglycans | 1 | 1995 | 79 | 0.030 |
Why?
|
| Hepatitis B | 1 | 1997 | 174 | 0.030 |
Why?
|
| Laminin | 1 | 1995 | 68 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2015 | 72 | 0.030 |
Why?
|
| Vitamin B Complex | 1 | 2015 | 38 | 0.030 |
Why?
|
| NIH 3T3 Cells | 2 | 2005 | 96 | 0.030 |
Why?
|
| Lipid Peroxidation | 1 | 2015 | 91 | 0.030 |
Why?
|
| Diffusion | 1 | 2015 | 59 | 0.030 |
Why?
|
| Lectins, C-Type | 1 | 2015 | 69 | 0.030 |
Why?
|
| Indazoles | 1 | 2015 | 35 | 0.030 |
Why?
|
| Drug Liberation | 1 | 2015 | 43 | 0.030 |
Why?
|
| Cytomegalovirus Retinitis | 1 | 1995 | 16 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 1996 | 124 | 0.030 |
Why?
|
| Toxoplasma | 1 | 1995 | 18 | 0.030 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2014 | 6 | 0.030 |
Why?
|
| Axons | 1 | 2018 | 384 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2016 | 363 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2016 | 442 | 0.030 |
Why?
|
| Antigens, Ly | 1 | 2014 | 33 | 0.030 |
Why?
|
| Adenoviruses, Human | 1 | 1995 | 97 | 0.030 |
Why?
|
| Alkylating Agents | 1 | 2014 | 6 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 1991 | 222 | 0.030 |
Why?
|
| Pseudomonas aeruginosa | 3 | 1990 | 175 | 0.030 |
Why?
|
| Herpes Simplex | 1 | 1995 | 56 | 0.030 |
Why?
|
| Morphogenesis | 1 | 1995 | 199 | 0.030 |
Why?
|
| Leukocytes | 1 | 2015 | 211 | 0.030 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 2 | 1990 | 15 | 0.030 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2013 | 22 | 0.030 |
Why?
|
| CD11c Antigen | 1 | 2013 | 40 | 0.030 |
Why?
|
| Lymphocyte Depletion | 1 | 2013 | 123 | 0.020 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 1993 | 59 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 1997 | 1261 | 0.020 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2013 | 6 | 0.020 |
Why?
|
| Cadaver | 1 | 1993 | 121 | 0.020 |
Why?
|
| Autocrine Communication | 1 | 2013 | 28 | 0.020 |
Why?
|
| Receptor, Muscarinic M3 | 1 | 2012 | 2 | 0.020 |
Why?
|
| Receptors, Interleukin | 1 | 2013 | 37 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2013 | 84 | 0.020 |
Why?
|
| Transcription Factor RelA | 1 | 2013 | 54 | 0.020 |
Why?
|
| Antibodies, Blocking | 1 | 2013 | 57 | 0.020 |
Why?
|
| Skin | 1 | 2016 | 553 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2012 | 64 | 0.020 |
Why?
|
| Mice, 129 Strain | 1 | 2012 | 97 | 0.020 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 1993 | 76 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 1993 | 452 | 0.020 |
Why?
|
| 3T3 Cells | 1 | 2012 | 121 | 0.020 |
Why?
|
| Nitriles | 1 | 2013 | 165 | 0.020 |
Why?
|
| Tobramycin | 1 | 1992 | 22 | 0.020 |
Why?
|
| Streptococcus | 1 | 1992 | 63 | 0.020 |
Why?
|
| Gram-Negative Bacteria | 1 | 1992 | 76 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 261 | 0.020 |
Why?
|
| Ambrosia | 1 | 2011 | 15 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2014 | 772 | 0.020 |
Why?
|
| Diglycerides | 1 | 2011 | 16 | 0.020 |
Why?
|
| Protein Binding | 1 | 2015 | 1712 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2012 | 230 | 0.020 |
Why?
|
| I-kappa B Kinase | 1 | 2011 | 57 | 0.020 |
Why?
|
| Culture Media, Serum-Free | 1 | 2011 | 23 | 0.020 |
Why?
|
| Cooking and Eating Utensils | 1 | 1991 | 3 | 0.020 |
Why?
|
| Cytoskeletal Proteins | 1 | 1992 | 279 | 0.020 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 1990 | 5 | 0.020 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 1990 | 10 | 0.020 |
Why?
|
| Receptors, Interleukin-17 | 1 | 2010 | 7 | 0.020 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 2 | 2001 | 21 | 0.020 |
Why?
|
| Sulfamethoxazole | 1 | 1990 | 1 | 0.020 |
Why?
|
| Trimethoprim | 1 | 1990 | 3 | 0.020 |
Why?
|
| Acyclovir | 1 | 1990 | 47 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2011 | 123 | 0.020 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 2 | 1 | 1990 | 5 | 0.020 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1990 | 40 | 0.020 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1990 | 32 | 0.020 |
Why?
|
| Herpesviridae | 1 | 1991 | 32 | 0.020 |
Why?
|
| Drug Contamination | 1 | 1990 | 36 | 0.020 |
Why?
|
| Gentamicins | 2 | 1988 | 87 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2013 | 372 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2013 | 469 | 0.020 |
Why?
|
| Rubella virus | 1 | 1990 | 5 | 0.020 |
Why?
|
| Antigens | 1 | 1990 | 149 | 0.020 |
Why?
|
| Receptors, OX40 | 1 | 2010 | 8 | 0.020 |
Why?
|
| CD3 Complex | 1 | 1990 | 93 | 0.020 |
Why?
|
| Quinolines | 1 | 2011 | 121 | 0.020 |
Why?
|
| DNA Probes | 1 | 2010 | 120 | 0.020 |
Why?
|
| Tumor Necrosis Factors | 1 | 2010 | 11 | 0.020 |
Why?
|
| Tuberculosis, Ocular | 1 | 1989 | 3 | 0.020 |
Why?
|
| Osmosis | 1 | 2010 | 17 | 0.020 |
Why?
|
| Receptors, Complement | 1 | 1990 | 31 | 0.020 |
Why?
|
| Tissue Donors | 2 | 1997 | 502 | 0.020 |
Why?
|
| Pollen | 1 | 2010 | 49 | 0.020 |
Why?
|
| Calibration | 1 | 1989 | 95 | 0.020 |
Why?
|
| Anesthetics | 1 | 1990 | 78 | 0.020 |
Why?
|
| Receptors, Virus | 1 | 1990 | 97 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2010 | 421 | 0.020 |
Why?
|
| Plant Proteins | 1 | 2010 | 89 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1996 | 1281 | 0.020 |
Why?
|
| Immune System Phenomena | 1 | 2009 | 2 | 0.020 |
Why?
|
| Miconazole | 1 | 1989 | 2 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 1990 | 570 | 0.020 |
Why?
|
| Infarction | 1 | 1989 | 20 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2010 | 418 | 0.020 |
Why?
|
| Interleukin-7 | 1 | 2009 | 46 | 0.020 |
Why?
|
| Thymus Gland | 1 | 2009 | 102 | 0.020 |
Why?
|
| Lymphogranuloma Venereum | 1 | 1988 | 2 | 0.020 |
Why?
|
| Retinal Vessels | 1 | 1989 | 52 | 0.020 |
Why?
|
| Staphylococcus epidermidis | 1 | 1988 | 40 | 0.020 |
Why?
|
| Texas | 1 | 2017 | 3629 | 0.020 |
Why?
|
| Benzamidines | 1 | 2008 | 10 | 0.020 |
Why?
|
| Methods | 1 | 1988 | 115 | 0.020 |
Why?
|
| Substance-Related Disorders | 2 | 1990 | 491 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 1990 | 241 | 0.020 |
Why?
|
| Vision, Binocular | 1 | 2008 | 31 | 0.020 |
Why?
|
| Suction | 1 | 1988 | 50 | 0.020 |
Why?
|
| Antiprotozoal Agents | 1 | 2008 | 42 | 0.020 |
Why?
|
| Equipment Design | 1 | 1989 | 557 | 0.020 |
Why?
|
| Electroretinography | 1 | 1988 | 107 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2010 | 421 | 0.020 |
Why?
|
| Eye Enucleation | 3 | 1993 | 34 | 0.020 |
Why?
|
| Cross Infection | 1 | 1991 | 339 | 0.020 |
Why?
|
| Pigment Epithelium of Eye | 1 | 1987 | 37 | 0.020 |
Why?
|
| Spleen | 1 | 2008 | 257 | 0.020 |
Why?
|
| Sensory Aids | 1 | 1987 | 1 | 0.020 |
Why?
|
| Panophthalmitis | 1 | 1987 | 2 | 0.020 |
Why?
|
| Bacillus cereus | 1 | 1987 | 10 | 0.020 |
Why?
|
| Parotid Gland | 1 | 1986 | 18 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 1008 | 0.020 |
Why?
|
| Salivary Glands | 1 | 1986 | 34 | 0.020 |
Why?
|
| Allergens | 1 | 2010 | 356 | 0.020 |
Why?
|
| Drug Synergism | 1 | 1987 | 239 | 0.020 |
Why?
|
| Vision, Ocular | 1 | 1988 | 127 | 0.020 |
Why?
|
| Cellulitis | 1 | 1987 | 62 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1990 | 503 | 0.020 |
Why?
|
| Biotin | 1 | 2006 | 39 | 0.020 |
Why?
|
| Reading | 1 | 1987 | 78 | 0.020 |
Why?
|
| Orbital Diseases | 1 | 1987 | 66 | 0.010 |
Why?
|
| Biomarkers, Tumor | 2 | 2005 | 1618 | 0.010 |
Why?
|
| Calcium | 1 | 2011 | 1043 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 2005 | 102 | 0.010 |
Why?
|
| Quality of Life | 1 | 2016 | 2116 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2006 | 171 | 0.010 |
Why?
|
| Mycobacterium tuberculosis | 1 | 1989 | 425 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 2005 | 235 | 0.010 |
Why?
|
| Florida | 2 | 1998 | 72 | 0.010 |
Why?
|
| Smad2 Protein | 1 | 2005 | 55 | 0.010 |
Why?
|
| Intraocular Pressure | 1 | 2005 | 132 | 0.010 |
Why?
|
| Clone Cells | 1 | 2005 | 171 | 0.010 |
Why?
|
| Nestin | 1 | 2004 | 14 | 0.010 |
Why?
|
| Receptors, Transferrin | 1 | 2004 | 12 | 0.010 |
Why?
|
| Genes, erbB-1 | 1 | 2004 | 9 | 0.010 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2004 | 27 | 0.010 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2004 | 134 | 0.010 |
Why?
|
| Integrins | 1 | 2004 | 90 | 0.010 |
Why?
|
| Bacteriological Techniques | 1 | 2003 | 86 | 0.010 |
Why?
|
| Cadherins | 1 | 2004 | 178 | 0.010 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2001 | 25 | 0.010 |
Why?
|
| Ribonucleases | 1 | 2001 | 41 | 0.010 |
Why?
|
| Blotting, Southern | 2 | 1990 | 208 | 0.010 |
Why?
|
| Eye Foreign Bodies | 1 | 2000 | 9 | 0.010 |
Why?
|
| Algorithms | 1 | 2006 | 1686 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2000 | 220 | 0.010 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 1998 | 25 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2004 | 1131 | 0.010 |
Why?
|
| Hepatitis B Core Antigens | 1 | 1997 | 14 | 0.010 |
Why?
|
| Hepatitis B Antibodies | 1 | 1997 | 24 | 0.010 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 1997 | 59 | 0.010 |
Why?
|
| Serologic Tests | 1 | 1997 | 125 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1997 | 213 | 0.010 |
Why?
|
| Fungi | 1 | 1996 | 73 | 0.010 |
Why?
|
| Prednisone | 1 | 1996 | 246 | 0.010 |
Why?
|
| Hepatitis B virus | 1 | 1997 | 143 | 0.010 |
Why?
|
| Injections | 1 | 1995 | 115 | 0.010 |
Why?
|
| Erythromycin | 1 | 1993 | 19 | 0.010 |
Why?
|
| Chlamydia Infections | 1 | 1993 | 53 | 0.010 |
Why?
|
| Lymphoid Tissue | 1 | 1992 | 48 | 0.010 |
Why?
|
| Herpes Zoster | 1 | 1992 | 25 | 0.010 |
Why?
|
| Virus Cultivation | 1 | 1992 | 70 | 0.010 |
Why?
|
| Cephalosporins | 1 | 1993 | 139 | 0.010 |
Why?
|
| Tissue Adhesives | 1 | 1992 | 40 | 0.010 |
Why?
|
| Propionibacterium | 1 | 1991 | 4 | 0.010 |
Why?
|
| Corynebacterium Infections | 1 | 1991 | 6 | 0.010 |
Why?
|
| Autoradiography | 1 | 1991 | 65 | 0.010 |
Why?
|
| Facial Paralysis | 1 | 1991 | 35 | 0.010 |
Why?
|
| Trabeculectomy | 1 | 1991 | 16 | 0.010 |
Why?
|
| Retinitis | 1 | 1991 | 12 | 0.010 |
Why?
|
| Equipment Contamination | 1 | 1991 | 42 | 0.010 |
Why?
|
| Colony Count, Microbial | 1 | 1990 | 87 | 0.010 |
Why?
|
| Disinfection | 1 | 1990 | 26 | 0.010 |
Why?
|
| Ketoconazole | 1 | 1990 | 10 | 0.010 |
Why?
|
| Flucytosine | 1 | 1990 | 10 | 0.010 |
Why?
|
| Receptors, Complement 3d | 1 | 1990 | 7 | 0.000 |
Why?
|
| Cross Reactions | 1 | 1990 | 188 | 0.000 |
Why?
|
| Glaucoma | 1 | 1991 | 87 | 0.000 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1990 | 299 | 0.000 |
Why?
|
| Reoperation | 1 | 1993 | 844 | 0.000 |
Why?
|
| Disposable Equipment | 1 | 1989 | 16 | 0.000 |
Why?
|
| Solutions | 1 | 1989 | 53 | 0.000 |
Why?
|
| Candida | 1 | 1990 | 79 | 0.000 |
Why?
|
| Fluorescein Angiography | 1 | 1989 | 64 | 0.000 |
Why?
|
| Drug Administration Routes | 1 | 1989 | 33 | 0.000 |
Why?
|
| Methicillin | 1 | 1988 | 43 | 0.000 |
Why?
|
| Cefazolin | 1 | 1988 | 20 | 0.000 |
Why?
|
| Cytomegalovirus Infections | 1 | 1991 | 225 | 0.000 |
Why?
|
| Chlamydia trachomatis | 1 | 1988 | 30 | 0.000 |
Why?
|
| Solvents | 1 | 1988 | 44 | 0.000 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1988 | 215 | 0.000 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 1988 | 1413 | 0.000 |
Why?
|